Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Aki Yoshida is active.

Publication


Featured researches published by Aki Yoshida.


Journal of Pharmaceutical Health Care and Sciences | 2018

Analyses of non-benzodiazepine-induced adverse events and prognosis in elderly patients based on the Japanese adverse drug event report database

Yoshihiro Noguchi; Anri Ueno; Hayato Katsuno; Manami Otsubo; Aki Yoshida; Yuta Kanematsu; Ikuto Sugita; Tomoya Tachi; Teruo Tsuchiya; Hitomi Teramachi

BackgroundThe contents of the guidelines for the use of non-benzodiazepines (Z-drugs) differ slightly between THE JAPANESE SOCIETY OF SLEEP RESEARCH and THE JAPAN GERIATRIC SOCIETY, and the recommended directions are conflicting. Therefore, we analyzed the use of the Japanese Adverse Drug Event Report database (JADER) for identifying adverse events (AEs) caused by Z-drugs and clarifying their occurrence trend and prognosis.MethodsThe signal value for comparison was calculated by using the proportional reporting ratio (PRR) and chi-squared test (χ2) results of data of elderly and non-elderly patients. Among AEs for which signals were detected in the elderly, we determined that those with lower signal values for non-elderly patients that were half the signal value of the elderly should be used with particular caution in the elderly. We also compared the prognoses.ResultsThe AEs with > 1 risk ratio (RR) in elderly and non-elderly patients were regarded as those that should be noted in the prognosis of AEs in elderly patients. Furthermore, 28 AEs were detected in elderly patients’ signals. In this study, in addition to movement disorders such as “falls” and “bone fractures,” identified by two academic societies, signal characteristics of the elderly were obtained for psychiatric disorders and eye disorders.ConclusionsThere was no difference in prognosis, but these disorders could reduce the quality of life of patients. Therefore, we consider that in prescribing appropriate drug therapy for insomnia, attention should be paid to the occurrence of the AEs caused by the Z-drugs revealed by this study and the guidelines.


International Journal of Health Planning and Management | 2018

Medical and economic factors influencing generic drug use in the Japanese public health system: Influencing factors in different populations

Tomoya Tachi; Kosuke Saito; Hiroki Esaki; Yuta Kanematsu; Aki Yoshida; Ikuto Sugita; Yoshihiro Noguchi; Teppei Makino; Umeda M; Masahiro Yasuda; Takashi Mizui; Chitoshi Goto; Hitomi Teramachi

Factors influencing generic drug use must be considered when new drug policies are established and initiatives are implemented to promote generic drug use. This study was conducted to elucidate medical and economic factors that influence generic drug use in the Japanese public health system by evaluating the degree of generic drug use via a multivariate analysis. We conducted a retrospective study of medications administered to inpatients at Gifu Municipal Hospital (Japan) from November 1 to 14, 2014. Details of inpatients (age, sex, and type of medical insurance) and the drugs administered (prescribing institution, dispensing pharmacy, price, and class) were assessed. A total of 1409 drugs (original, 639; generic, 770) were analyzed. Multivariate analysis showed significant differences in out-of-pocket medical fees [odds ratio (OR), 0.595], drugs prescribed at Gifu Municipal Hospital (OR, 1.811), drugs prepared at a health insurance pharmacy (OR, 1.541), drugs containing the same active substances as in the generic drugs used at Gifu Municipal Hospital (OR, 3.712), and drugs costing ≥30 yen and containing the same active substance/having the same specifications (OR, 0.516). Drugs prescribed at a large key hospital in the community with high adoption rates of generic drugs, drugs containing the same active substances as the generic drugs adopted by the hospital, and drugs prepared at health insurance pharmacies contributed to a more frequent use of generic drugs. By contrast, out-of-pocket medical fees and being prescribed expensive drugs contributed to the less frequent use of generic drugs.


Frontiers in Pharmacology | 2018

A New Search Method Using Association Rule Mining for Drug-Drug Interaction Based on Spontaneous Report System

Yoshihiro Noguchi; Anri Ueno; Manami Otsubo; Hayato Katsuno; Ikuto Sugita; Yuta Kanematsu; Aki Yoshida; Hiroki Esaki; Tomoya Tachi; Hitomi Teramachi

Background: Adverse events (AEs) can be caused not only by one drug but also by the interaction between two or more drugs. Therefore, clarifying whether an AE is due to a specific suspect drug or drug-drug interaction (DDI) is useful information for proper use of drugs. Whereas previous reports on the search for drug-induced AEs with signal detection using spontaneous reporting systems (SRSs) are numerous, reports on drug interactions are limited. This is because in methods that use “a safety signal indicator” (signal), which is frequently used in pharmacovigilance, a huge number of combinations must be prepared when signal detection is performed, and each risk index must be calculated, which makes interaction search appear unrealistic. Objective: In this paper, we propose association rule mining (AR) using large dataset analysis as an alternative to the conventional methods (additive interaction model (AI) and multiplicative interaction model (MI)). Methods: The data source used was the Japanese Adverse Drug Event Report database. The combination of drugs for which the risk index is detected by the “combination risk ratio (CR)” as the target was assumed to be true data, and the accuracy of signal detection using the AR methods was evaluated in terms of sensitivity, specificity, Youdens index, F-score. Results: Our experimental results targeting Stevens-Johnson syndrome indicate that AR has a sensitivity of 99.05%, specificity of 92.60%, Youdens index of 0.917, F-score of 0.876, AI has a sensitivity of 95.62%, specificity of 96.92%, Youdens index of 0.925, and F-score of 0.924, and MI has a sensitivity of 65.46%, specificity of 98.78%, Youdens index of 0.642, and F-score of 0.771. This result was about the same level as or higher than the conventional method. Conclusions: If you use similar calculation methods to create combinations from the database, not only for SJS, but for all AEs, the number of combinations would be so enormous that it would be difficult to perform the calculations. However, in the AR method, the “Apriori algorithm” is used to reduce the number of calculations. Thus, the proposed method has the same detection power as the conventional methods, with the significant advantage that its calculation process is simple.


BMC Bioinformatics | 2018

A simple method for exploring adverse drug events in patients with different primary diseases using spontaneous reporting system

Yoshihiro Noguchi; Anri Ueno; Manami Otsubo; Hayato Katsuno; Ikuto Sugita; Yuta Kanematsu; Aki Yoshida; Hiroki Esaki; Tomoya Tachi; Hitomi Teramachi

BackgroundPatient background (e.g. age, sex, and primary disease) is an important factor to consider when monitoring adverse drug events (ADEs) for the purpose of pharmacovigilance. However, in disproportionality methods, when additional factors are considered, the number of combinations that have to be computed increases, and it becomes very difficult to explore the whole spontaneous reporting system (SRS). Since the signals need to be detected quickly in pharmacovigilance, a simple exploration method is required. Although association rule mining (AR) is commonly used for the analysis of large data, its application to pharmacovigilance is rare and there are almost no studies comparing AR with conventional signal detection methods.MethodsIn this study, in order to establish a simple method to explore ADEs in patients with kidney or liver injury as a background disease, the AR and proportional reporting ratio (PRR) signal detection methods were compared. We used oral medicine SRS data from the Japanese Adverse Drug Event Report database (JADER), and used AR as the proposed search method and PRR as the conventional method for comparison. “Rule count ≥ 3”, “min lift value > 1”, and “min conviction value > 1” were used as the AR detection criteria, and the PRR detection criteria were “Rule count ≥3”, “PRR ≥ 2”, and “χ2 ≥ 4”.ResultsIn patients with kidney injury, the AR method had a sensitivity of 99.58%, specificity of 94.99%, and Youden’s index of 0.946, while in patients with liver injury, the sensitivity, specificity, and Youden’s index were 99.57%, 94.87%, and 0.944, respectively. Additionally, the lift value and the strength of the signal were positively correlated.ConclusionsIt was suggested that computation using AR might be simple with the detection power equivalent to that of the conventional signal detection method as PRR. In addition, AR can theoretically be applicable to SRS other than JADER. Therefore, complicated conditions (patient’s background etc.) that must take factors other than the ADE into consideration can be easily explored by selecting the AR as the first screening for ADE exploration in pharmacovigilance using SRS.


Frontiers in Pharmacology | 2018

The Effect of Quality of Life on Medication Compliance Among Dialysis Patients

Hiroyuki Nagasawa; Tomoya Tachi; Ikuto Sugita; Hiroki Esaki; Aki Yoshida; Yuta Kanematsu; Yoshihiro Noguchi; Yukio Kobayashi; Etsuko Ichikawa; Teruo Tsuchiya; Hitomi Teramachi

Dialysis treatment is known to lead to reduced quality of life (QOL) among patients. This decreased QOL is believed to influence medication compliance, although this effect has not yet been clarified. In this study, we investigated whether decreased QOL due to dialysis treatment does in fact influence medication compliance. Participants were 92 patients who self-managed their medication and were receiving dialysis treatment at Secomedic Hospital or Chiba Central Medical Center. We surveyed their age, sex, dialysis period, and medication management situation, and administered the EQ-5D and Kidney Disease Quality of Life Instrument–Short Form. A multiple logistic regression analysis with medication compliance as the dependent variable and QOL as the independent variable was conducted. The recovery rate and effective response rate were both 100%. The results indicated that patients with good sleep QOL (mean or above) had higher odds of medication compliance (odds ratio, 3.36; 95% confidence interval, 1.26–8.96; P = 0.016). Therefore, improving the quality of sleep of dialysis patients might help to improve their medication compliance.


Frontiers in Pharmacology | 2017

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus

Hiroki Esaki; Tomoya Tachi; Chitoshi Goto; Ikuto Sugita; Yuta Kanematsu; Aki Yoshida; Kosuke Saito; Yoshihiro Noguchi; Yuki Ohno; Satoshi Aoyama; Masahiro Yasuda; Takashi Mizui; Masumi Yamamura; Hitomi Teramachi

Diabetic nephropathy is one of three major complications of diabetes mellitus, often leading to chronic renal failure requiring dialysis. Recently developed dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit renoprotective effects in addition to antihyperglycemic effects. In this study, we retrospectively investigated temporal changes in the renal function index of patients with type 2 diabetes mellitus (DM) and examined the influence of DPP-4 inhibitors on renal function. Patients with type 2 DM (>18 years old) prescribed hypoglycemic agents at Gifu Municipal Hospital for ≥3 months between March 2010 and April 2014 were included in the study. Renal function was evaluated as estimated the decline in 12-month glomerular filtration rate from the baseline in patients receiving and not receiving DPP-4 inhibitors. Patient data from the DPP-4 inhibitor-treated (501 patients, 58.6%) and untreated (354, 41.4%) groups were analyzed using multiple logistic regression analysis, as well as Cox proportional-hazards regression analysis (616, 55.6% and 491, 44.4%, for DPP-4 inhibitors-treated and untreated groups). Multiple logistic regression analysis indicated that DPP-4 inhibitors significantly lowered the estimated glomerular filtration rate (eGFR) decline [20% over 12 months; odds ratio (OR), 0.626; 95% confidence interval [CI], 0.409–0.958; P = 0.031]. Similar results were obtained using Cox proportional-hazards regression analysis (hazard ratio [HR], 0.707; 95% CI, 0.572–0.874; P = 0.001). These findings suggest that DPP-4 inhibitors suppress the decrease of estimated glomerular filtration rate in patients with type 2 DM and show a renoprotective effect.


Iyakuhin Johogaku | 2017

Search for Oral Medicine That Might Exacerbate the Prognosis of Adverse Drug Events in Elderly Patients

Yoshihiro Noguchi; Yuta Hayashi; Aki Yoshida; Ikuto Sugita; Hiroki Esaki; Kousuke Saito; Kazumasa Usui; Misa Kato; Tomoya Tachi; Hitomi Teramachi


Iyakuhin Johogaku | 2016

Pharmacoepidemiological Examination for the Safety of the Oral laxatives in the Elderly Patients

Yoshihiro Noguchi; Yuta Hayashi; Aki Yoshida; Ikuto Sugita; Hiroki Esaki; Kousuke Saito; Kazumasa Usui; Misa Kato; Tomoya Tachi; Hitomi Teramachi


Journal of Pharmaceutical Health Care and Sciences | 2018

Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database

Yoshihiro Noguchi; Hayato Katsuno; Anri Ueno; Manami Otsubo; Aki Yoshida; Yuta Kanematsu; Ikuto Sugita; Hiroki Esaki; Tomoya Tachi; Teruo Tsuchiya; Hitomi Teramachi


Journal of Pharmaceutical Health Care and Sciences | 2018

The adoption of generic drugs by a hospital: effects on drug dispensation among community pharmacies

Tomoya Tachi; Kosuke Saito; Hiroki Esaki; Ikuto Sugita; Aki Yoshida; Yuta Kanematsu; Yoshihiro Noguchi; Umeda M; Masahiro Yasuda; Takashi Mizui; Teruo Tsuchiya; Chitoshi Goto; Hitomi Teramachi

Collaboration


Dive into the Aki Yoshida's collaboration.

Top Co-Authors

Avatar

Hitomi Teramachi

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Ikuto Sugita

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Tomoya Tachi

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Yoshihiro Noguchi

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Hiroki Esaki

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Yuta Kanematsu

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Anri Ueno

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Hayato Katsuno

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Manami Otsubo

Gifu Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Yuta Hayashi

Gifu Pharmaceutical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge